Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 4 Week Open, Multi-center Study Evaluating the Safety of Levocetirizine 1.25 mg b.i.d. Given as 0.5 mg/mL Oral Solution in 2 to 6 Year-old Children Suffering From Allergic Rhinitis.

NCT00152412 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00152412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00152412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 4 Week Open, Multi-center Study Evaluating the Safety of Levocetirizine 1.25 mg b.i.d. Given as 0.5 mg/mL Oral Solution in 2 to 6 Year-old Children Suffering From Allergic Rhinitis.
Lead sponsor
UCB Pharma
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2004
Completion date
December 31, 2004
Enrollment
30
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

allergic rhinitis